PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances
about
Akt and mTOR in B Cell Activation and DifferentiationAre we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemiaTargeting p110gamma in gastrointestinal cancers: attack on multiple frontsIdentifying novel spatiotemporal regulators of innate immunityNew strategies in chronic lymphocytic leukemia: shifting treatment paradigmsIdelalisib for the treatment of chronic lymphocytic leukemiaA Conditional Knockout Mouse Model Reveals That Calponin-3 Is Dispensable for Early B Cell DevelopmentPI3Kδ promotes CD4(+) T-cell interactions with antigen-presenting cells by increasing LFA-1 binding to ICAM-1.Signaling by the phosphoinositide 3-kinase family in immune cellsPI3K p110δ is expressed by gp38(-)CD31(+) and gp38(+)CD31(+) spleen stromal cells and regulates their CCL19, CCL21, and LTβR mRNA levelsPI3K and cancer: lessons, challenges and opportunitiesPhase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemiaA virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity against multiple myeloma in vitro and in vivoGenetic associations with micronutrient levels identified in immune and gastrointestinal networks.PI3Kδ is essential for tumor clearance mediated by cytotoxic T lymphocytes.B-cell receptor signaling as a driver of lymphoma development and evolution.Development and application of PI3K assays for novel drug discovery.PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors.PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.All PI3Kinase signaling is not mTOR: dissecting mTOR-dependent and independent signaling pathways in T cells.Coordinated loss of microRNA group causes defenseless signaling in malignant lymphoma.Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLLSynergistic suppression of the PI3K inhibitor CAL-101 with bortezomib on mantle cell lymphoma growthGenetic variants in PI3K/AKT pathway are associated with severe radiation pneumonitis in lung cancer patients treated with radiation therapyEmerging role of kinase-targeted strategies in chronic lymphocytic leukemia.Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas.p110δ PI3 kinase pathway: emerging roles in cancer.An Emerging Role for PI5P in T Cell Biology.Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia.Transition from heterotypic to homotypic PDK1 homodimerization is essential for TCR-mediated NF-κB activation.The Nuclear Zinc Finger Protein Zfat Maintains FoxO1 Protein Levels in Peripheral T Cells by Regulating the Activities of Autophagy and the Akt Signaling Pathway.The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways.Cross talk between the Akt and p38α pathways in macrophages downstream of Toll-like receptor signaling.Antigen-affinity controls pre-germinal centser B cell selection by promoting Mcl-1 induction through BAFF receptor signaling.Context-specific BAFF-R signaling by the NF-κB and PI3K pathwaysInnate PI3K p110δ regulates Th1/Th17 development and microbiota-dependent colitis.A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth.Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis.
P2860
Q21131224-44BB0FB4-1EC5-42B7-A8EF-5B31AC681471Q24597424-B2D7815C-F106-4718-8AC8-F778B0FE0C56Q26775506-1BC8C777-7291-4E08-BA31-02429937A227Q26823575-ADC3D66A-4A73-47E7-8134-BB570317B9D7Q26823854-B7441586-61D2-4618-B92C-F575D02D5297Q26828496-0550A414-2CED-44B5-890F-D2DF3A76DB0FQ27015826-D38729F4-C1D2-4FE1-8E40-5F4BE04E79C8Q27305358-91B6EC7F-6C23-4737-A26C-D7B2B31C4F00Q27323048-E00D5A41-BF34-4C3B-834B-B1BFBF6DC593Q28283677-0B886AE4-3805-4852-86C3-35CCD372AD55Q28512141-2B7AE0A5-A2A8-4537-A082-792969C45A7EQ30080017-6873CE95-6A7A-4E3C-8D23-AB3B962E12C6Q33433009-DE923649-61E2-4EC3-9FA9-9F8F39BD143EQ33873323-C8E02B19-7276-4D9A-916A-F36C01DD7A55Q33977088-28D4542D-9101-45BA-9AE6-9B8162F764A1Q34212877-40646860-5276-4780-9F35-3D24BA538CBFQ34342465-6BCD49C8-0084-49AE-9E9C-D3C9681B9CA6Q34398579-C0CF801B-3535-4708-B94E-056E7FA832C1Q35535379-C46927D5-137D-490A-BDFF-C42FD0D5D3A1Q35833018-82766CFF-5018-4D72-BB03-E2CE7A50D208Q36086507-BA0488BA-13CF-4E3E-830C-3C7F445D3F6FQ36303948-C0F50759-B0FB-475A-8ECC-656BA7E1B6DFQ36350416-D77D59D3-E02B-464C-B948-44D70451E97EQ36404778-6C2E4DAB-F2CB-4A8E-89E0-09528082D2C1Q36445743-A8E632D1-F05E-4919-8BCB-9CEF6A1EB919Q36451560-EC27EC3D-F515-4A38-9549-8EBB891627D2Q36462375-50B40A98-94CD-4565-B099-F7CF75073971Q36498356-8AABA800-E405-4456-9BD8-7C7A8B85842BQ36647928-D8ADFE5E-A447-400B-B863-D5DFA513C0EDQ36732873-F8D2E0EF-58AA-4D28-A17E-8B32E1F5A460Q36737287-2C8C88E6-28BA-4D9D-8B49-85F285DC17FBQ36876167-35E8DFF5-B9C4-4FD9-A755-E72923CF35EAQ37098954-2804520B-0187-4C05-B603-4F395EB901B7Q37200384-469F9025-8D79-4550-B638-2BDDD38C1ADAQ37265027-6D2F7982-FE53-41EB-8E49-9FD216478485Q37352687-13795828-E0EA-4A88-B660-28B41FAD9F49Q37460813-D945D8B8-FF31-4789-B982-C3621D56A494Q37711217-D1AC5897-A064-4EE6-BC30-A03FD6E2CCBEQ37729587-1A140308-D55B-49F3-B515-61CB62C979E5Q37730801-B88E693B-6291-4E9A-9163-791320CC0B35
P2860
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances
@ast
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances
@en
type
label
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances
@ast
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances
@en
prefLabel
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances
@ast
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances
@en
P2860
P356
P1433
P1476
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances
@en
P2093
David A Fruman
P2860
P304
P356
10.1042/BJ20112092
P407
P577
2012-03-01T00:00:00Z